AMIX at a glance
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
AMIX price history
Loading recent earnings…
Investment thesis
What must happen next
Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product.HoldingMateriality: High
GAAP annual revenue was $0 in FY2023, FY2024, FY2025, and FY2026, confirming there is no commercial adoption yet. If clinical proof arrives, the company can begin to build a real business; if it does not, equity value remains a melting development option.
Watch: A pivotal or feasibility study fails to show a clinically meaningful benefit or produces a safety signal.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $0 in FY2023, FY2024, FY2025, and FY2026, confirming there is no commercial adoption yet.
Open source ↗Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones.WeakeningMateriality: High
Cash was $7.004 million at FY2026 year-end. Even good science can be a bad stock if the next capital raise transfers most of the upside to new investors.
Watch: The company cannot raise equity or strategic capital before a major clinical or regulatory milestone.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $7.004 million at FY2026 year-end.
Open source ↗Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead.WeakeningMateriality: Medium
GAAP operating cash flow was negative $1.854 million in FY2023, negative $6.600 million in FY2024, negative $8.258 million in FY2025, and negative $12.282 million in FY2026. Capital discipline determines whether each dollar of dilution increases the probability of success or merely shortens runway.
Watch: Clinical timelines slip while cash burn continues at the current or higher pace.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP operating cash flow was negative $1.854 million in FY2023, negative $6.600 million in FY2024, negative $8.258 million in FY2025.
Open source ↗Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles.StrengtheningMateriality: Medium
Liabilities were $1.705 million at FY2026 year-end, broadly stable versus $1.707 million at FY2025 year-end. For a pre-revenue issuer, who owns the claims on the asset can matter as much as whether the asset ultimately works.
Watch: The company issues secured debt or convertible securities with senior claims on the technology.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Liabilities were $1.705 million at FY2026 year-end, broadly stable versus $1.707 million at FY2025 year-end.
Open source ↗Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel.HoldingMateriality: Medium
The company describes itself as a development-stage medical device company advancing technologies for sensing and treating disorders of the nervous system. Differentiation is what would allow reimbursement, physician adoption, and durable economics; without it, commercialization could fail even after technical development.
Watch: Incumbent neuromodulation, ablation, or diagnostic-device companies such as Medtronic, Boston Scientific, or Abbott demonstrate comparable outcomes with established platforms.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as a development-stage medical device company advancing technologies for sensing and treating disorders of the nervous.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product. If clinical proof arrives, the company can begin to build a real business; if it does not, equity value remains a melting development option.
Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones. Even good science can be a bad stock if the next capital raise transfers most of the upside to new investors.
Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead. Capital discipline determines whether each dollar of dilution increases the probability of success or merely shortens runway.
Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles. For a pre-revenue issuer, who owns the claims on the asset can matter as much as whether the asset ultimately works.
Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel. Differentiation is what would allow reimbursement, physician adoption, and durable economics; without it, commercialization could fail even after technical development.
All standing thesis claims
Original report summary
its nervous-system sensing/treatment technology produces clinical proof before cash runway and dilution overwhelm equity holders.
Bull case and bear case
Bull case and bear case for Autonomix Medical
Where the evidence on Autonomix Medical disagrees: Mixed on the latest evidence (Oct 12, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.
Bull case: what the evidence supports
Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product.
Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles.
Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel.
Bear case: what the evidence questions
Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones.
Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead.
Company research
Research on Autonomix Medical
- Reporting · Autonomix Medical, Inc. (NASDAQ: AMIX) Gets a Clearer FDA Path
The company sees a potential 15-month route to initial clearance, but its filing says it needs $25 million to $30 million to reach commercialization.
Thesis-Break Engine
Thesis-break watch · Autonomix Medical
No break has crossed Autonomix Medical’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
Autonomix Medical filed an SEC 8-K on 2026-09-16: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Autonomix Medical filed an SEC 8-K on 2026-08-26: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedOther material event.
Autonomix Medical filed an SEC 8-K on 2026-07-28: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A pivotal or feasibility study fails to show a clinically meaningful benefit or produces a safety signal.
- The company cannot raise equity or strategic capital before a major clinical or regulatory milestone.
- Clinical timelines slip while cash burn continues at the current or higher pace.
- The company issues secured debt or convertible securities with senior claims on the technology.
- Incumbent neuromodulation, ablation, or diagnostic-device companies such as Medtronic, Boston Scientific, or Abbott demonstrate comparable outcomes with established platforms.
AMIX news
Loading headlines…
Financial statements
AMIX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AMIX: quick answers
- What is AMIX's short interest?
- As of October 30, 2026, 55,505 AMIX shares were sold short, down 5.9% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. AMIX short interest history

